The Cleveland Clinic, Lou Ruvo Center for Brain Health is now actively recruiting participants for a new, relapsing-remitting multiple sclerosis treatment title called DELIVER-MS. Cleveland Clinic has taken a leading position in this multi-study study to compare the benefits and risks of two common treatment approaches for multiple sclerosis to determine which is the better course. The two clinical options include:
- A highly-effective treatment early in the disease study
- Standard escalation approach using moderately effective medications and escalates as needed
This trial represents the first time the two approaches have been compared head-to-head. The 3-year, 800 participant study will be enrolled and divided into two sub-groups including:
- Randomized clinical trial
Those participants assigned to the randomized trial will be categorized to either the early-highly effective treatment approach or the standard escalation approach.
DELIVER-MS is sponsored by the Patient Centered Outcomes Research Institute as well as the National Multiple Sclerosis Society with research driven by Cleveland Clinic. The Lou Ruvo Center for Brain Health is working in cooperation with Cleveland Clinic in Ohio to conduct the study.